Toxicological evaluation of long-term intravenous administration of amitraz in horses


With the aim of determining the possible toxicity of amitraz after its prolonged use in horses, six English Thoroughbred horses received intravenous injections of amitraz (0.05, 0.10 or 0.15 mg/kg) weekly for four months, constituting the experimental group. Eight other animals (control group), via the same route following the same drug administration schedule and period of time, received the vehicle, dimethylformamide. At the end of this period, blood was collected from all the animals, and a comparison was made of the means of the values obtained for the various blood analyses: complete hemogram, alkaline phosphatase, gamma-glutamyltransferase, blood urea nitrogen, lactate dehydrogenase, aspartate aminotransferase, creatine phosphokinase, glucose, albumin, total protein, creatinine, Na+ , K+, Cl- and CO2. The results for the biochemical characteristics showed that only the mean value for urea of the animals submitted to treatment with amitraz was significantly different than the mean value obtained for the control group. The analyses of the hematological characteristics showed that no significant differences between groups were observed. Similarly, the measurement of blood electrolyte levels demonstrated that long-term treatment with amitraz did not cause significant changes in the variables analyzed. The results indicate that amitraz, given in the doses employed in this study, did not show signs of inducing toxic effects in vital organs, even after prolonged administration.

Document Type


Publication Date


Notes/Citation Information

Queiroz-Neto, A., D'Angelis, F. H. F., Harkins, J. D., & Tobin, T.. (2002). Toxicological evaluation of long-term intravenous administration of amitraz in horses. Arquivo Brasileiro De Medicina Veterinária E Zootecnia, 54(4), 345–350.

Digital Object Identifier (DOI)


Funding Information

This work was supported by Brazilian research foundations Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) and Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq).